FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116737560> ?p ?o ?g. }

• W2116737560 endingPage "748" @default.
• W2116737560 startingPage "742" @default.
• W2116737560 abstract "Clinical use of protease inhibitors (PIs) and nucleoside reverse transcriptase inhibitors (NRTIs) may be hampered by toxicity, interactions or resistance issues. Simple and effective antiretroviral regimens avoiding both drug classes may be needed for selected patients.This was a prospective cohort study. Virologically suppressed patients on PI or NRTI regimens, with problems of tolerability, safety concerns due to comorbidities or risk of drug interactions for both PIs and NRTIs, were given the opportunity to switch their regimen to etravirine plus raltegravir. Patients were required not to have prior virological failure to raltegravir and if there was prior non-nucleoside reverse transcriptase inhibitor (NNRTI) virological failure, only patients in whom efficacy of etravirine could be anticipated through the Stanford Drug Resistance Database were included. Follow-up was scheduled for at least 48 weeks, unless the patient was lost to follow-up or discontinued therapy.Twenty-five patients were included. Their median age was 54 years; they had a median of 16 years on antiretroviral therapy and a median of nine previous regimens; 21 (84%) patients had previous virological failure; and 15 (60%) patients had a genotypic test that showed three or more NRTI mutations in 9 (36%), four or more PI mutations in 11 (44%) and at least one NNRTI mutation in 8 (32%) patients. At 48 weeks efficacy was 84% (95% CI 65.3%-93.6%) by intent-to-treat analysis and 91.3% (95% CI 73.2%-97.6%) by per-protocol analysis. One (4%) patient died, two (8%) discontinued due to intolerance and one (4%) experienced virological failure. The CD4/CD8 ratio and plasma lipids improved.Dual therapy with etravirine plus raltegravir was well tolerated and maintained durable viral suppression in selected virologically suppressed patients for whom both PI and NRTI therapy was challenging." @default.
• W2116737560 created "2016-06-24" @default.
• W2116737560 creator A5000222212 @default.
• W2116737560 creator A5018384098 @default.
• W2116737560 creator A5033023982 @default.
• W2116737560 creator A5033344017 @default.
• W2116737560 creator A5057724971 @default.
• W2116737560 creator A5061062608 @default.
• W2116737560 creator A5064033407 @default.
• W2116737560 creator A5081538828 @default.
• W2116737560 creator A5085047733 @default.
• W2116737560 creator A5089446001 @default.
• W2116737560 date "2013-10-14" @default.
• W2116737560 modified "2023-10-18" @default.
• W2116737560 title "Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study" @default.
• W2116737560 cites W1980151112 @default.
• W2116737560 cites W1985824057 @default.
• W2116737560 cites W2025409162 @default.
• W2116737560 cites W2036917641 @default.
• W2116737560 cites W2039777415 @default.
• W2116737560 cites W2046246036 @default.
• W2116737560 cites W2046594098 @default.
• W2116737560 cites W2053570554 @default.
• W2116737560 cites W2055291483 @default.
• W2116737560 cites W2058498750 @default.
• W2116737560 cites W2077535491 @default.
• W2116737560 cites W2097051924 @default.
• W2116737560 cites W2110559078 @default.
• W2116737560 cites W2121179908 @default.
• W2116737560 cites W2123055341 @default.
• W2116737560 cites W2135397849 @default.
• W2116737560 cites W2149717057 @default.
• W2116737560 cites W2150504993 @default.
• W2116737560 cites W2154164013 @default.
• W2116737560 cites W2159328065 @default.
• W2116737560 cites W2162544188 @default.
• W2116737560 cites W2166406123 @default.
• W2116737560 cites W2167865974 @default.
• W2116737560 cites W2168518701 @default.
• W2116737560 cites W2169218167 @default.
• W2116737560 cites W4241267536 @default.
• W2116737560 doi "https://doi.org/10.1093/jac/dkt406" @default.
• W2116737560 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24128667" @default.
• W2116737560 hasPublicationYear "2013" @default.
• W2116737560 type Work @default.
• W2116737560 sameAs 2116737560 @default.
• W2116737560 citedByCount "33" @default.
• W2116737560 countsByYear W21167375602014 @default.
• W2116737560 countsByYear W21167375602015 @default.
• W2116737560 countsByYear W21167375602016 @default.
• W2116737560 countsByYear W21167375602017 @default.
• W2116737560 countsByYear W21167375602018 @default.
• W2116737560 countsByYear W21167375602019 @default.
• W2116737560 countsByYear W21167375602020 @default.
• W2116737560 countsByYear W21167375602021 @default.
• W2116737560 countsByYear W21167375602023 @default.
• W2116737560 crossrefType "journal-article" @default.
• W2116737560 hasAuthorship W2116737560A5000222212 @default.
• W2116737560 hasAuthorship W2116737560A5018384098 @default.
• W2116737560 hasAuthorship W2116737560A5033023982 @default.
• W2116737560 hasAuthorship W2116737560A5033344017 @default.
• W2116737560 hasAuthorship W2116737560A5057724971 @default.
• W2116737560 hasAuthorship W2116737560A5061062608 @default.
• W2116737560 hasAuthorship W2116737560A5064033407 @default.
• W2116737560 hasAuthorship W2116737560A5081538828 @default.
• W2116737560 hasAuthorship W2116737560A5085047733 @default.
• W2116737560 hasAuthorship W2116737560A5089446001 @default.
• W2116737560 hasConcept C114851261 @default.
• W2116737560 hasConcept C126322002 @default.
• W2116737560 hasConcept C142462285 @default.
• W2116737560 hasConcept C159047783 @default.
• W2116737560 hasConcept C188816634 @default.
• W2116737560 hasConcept C197934379 @default.
• W2116737560 hasConcept C2777302000 @default.
• W2116737560 hasConcept C2777351918 @default.
• W2116737560 hasConcept C2778375690 @default.
• W2116737560 hasConcept C2780345285 @default.
• W2116737560 hasConcept C2780404665 @default.
• W2116737560 hasConcept C2781143361 @default.
• W2116737560 hasConcept C2781413609 @default.
• W2116737560 hasConcept C2993143319 @default.
• W2116737560 hasConcept C3013748606 @default.
• W2116737560 hasConcept C71924100 @default.
• W2116737560 hasConcept C86803240 @default.
• W2116737560 hasConcept C89423630 @default.
• W2116737560 hasConceptScore W2116737560C114851261 @default.
• W2116737560 hasConceptScore W2116737560C126322002 @default.
• W2116737560 hasConceptScore W2116737560C142462285 @default.
• W2116737560 hasConceptScore W2116737560C159047783 @default.
• W2116737560 hasConceptScore W2116737560C188816634 @default.
• W2116737560 hasConceptScore W2116737560C197934379 @default.
• W2116737560 hasConceptScore W2116737560C2777302000 @default.
• W2116737560 hasConceptScore W2116737560C2777351918 @default.
• W2116737560 hasConceptScore W2116737560C2778375690 @default.
• W2116737560 hasConceptScore W2116737560C2780345285 @default.
• W2116737560 hasConceptScore W2116737560C2780404665 @default.
• W2116737560 hasConceptScore W2116737560C2781143361 @default.
• W2116737560 hasConceptScore W2116737560C2781413609 @default.

• next